Effect of tibolone versus hormone replacement therapy on lower urinary tract symptoms and sexual function
CONCLUSIONS: Despite the limited effect, tibolone seems to have more benefit in nocturia than HRT. In addition, tibolone seems to have benefits on overall low urinary tract storage symptoms; and both tibolone and HRT seem to have beneficial effects on female sexual function, despite there were no significant differences between tibolone and HRT.PMID:38092655 | DOI:10.1016/j.jfma.2023.12.007 (Source: J Formos Med Assoc)
Source: J Formos Med Assoc - December 13, 2023 Category: General Medicine Authors: Sheng-Mou Hsiao Shiow-Ru Chang Source Type: research
The comparison between fixed versus degressive doses of medroxyprogesterone acetate combined with letrozole in patients of progestin-primed ovarian stimulation protocol: a propensity score-matched study
ConclusionThe combination of a degressive MPA dose with LE proved effective in reducing the total MPA dosage with comparable premature LH surge and pregnancy outcomes in women undergoing the PPOS protocol. (Source: Frontiers in Endocrinology)
Source: Frontiers in Endocrinology - December 12, 2023 Category: Endocrinology Source Type: research
Vagino-Laparoscopic Conservative Strategy of Hysterectomy in Indicated Cases of Severe Pelvic Endometriosis Followed by 24 Months of Depot-Medroxyprogesterone Acetate Therapy — A Symptom-Solving Treatment Model to Ease Surgical Challenges
(Source: International Journal of Womens Health)
Source: International Journal of Womens Health - December 4, 2023 Category: OBGYN Tags: International Journal of Women's Health Source Type: research
Progestins and breast cancer hallmarks: The role of the ERK1/2 and JNK pathways in estrogen receptor positive breast cancer cells
J Steroid Biochem Mol Biol. 2023 Dec 2:106440. doi: 10.1016/j.jsbmb.2023.106440. Online ahead of print.ABSTRACTProgestins used in hormonal contraceptives and menopausal hormone therapy (MHT) have been linked to increased breast cancer risk. Whether the association holds for all progestins is unclear and the underlying mechanisms remain poorly understood. We directly compared the effects of four progestins (medroxyprogesterone acetate (MPA), norethisterone acetate (NET-A), levonorgestrel (LNG) and drospirenone (DRSP)) to each other and the natural progestogen progesterone (P4) on selected cancer hallmarks. To provide mechan...
Source: Mol Biol Cell - December 4, 2023 Category: Molecular Biology Authors: Renate Louw-du Toit Mishkah Simons Donita Africander Source Type: research
Progestins and breast cancer hallmarks: The role of the ERK1/2 and JNK pathways in estrogen receptor positive breast cancer cells
J Steroid Biochem Mol Biol. 2023 Dec 2:106440. doi: 10.1016/j.jsbmb.2023.106440. Online ahead of print.ABSTRACTProgestins used in hormonal contraceptives and menopausal hormone therapy (MHT) have been linked to increased breast cancer risk. Whether the association holds for all progestins is unclear and the underlying mechanisms remain poorly understood. We directly compared the effects of four progestins (medroxyprogesterone acetate (MPA), norethisterone acetate (NET-A), levonorgestrel (LNG) and drospirenone (DRSP)) to each other and the natural progestogen progesterone (P4) on selected cancer hallmarks. To provide mechan...
Source: Mol Biol Cell - December 4, 2023 Category: Molecular Biology Authors: Renate Louw-du Toit Mishkah Simons Donita Africander Source Type: research
Progestogens for prevention of luteinising hormone (LH) surge in women undergoing controlled ovarian hyperstimulation as part of an assisted reproductive technology (ART) cycle
CONCLUSIONS: Little or no differences in LBR may exist when comparing MPA 4 mg with GnRH agonists in normo-responders. OPCR may be slightly increased in the MPA 4 mg group, but MPA 4 mg reduces the doses of gonadotropins in comparison to GnRH agonists. Little or no differences in OPCR may exist between progestogens and GnRH antagonists in normo-responders and donors. However, micronised progesterone could improve by 2 to 6 MII oocytes. When comparing one progestogen to another, dydrogesterone suggested slightly lower OPCR than MPA and micronised progesterone, and MPA suggested slightly lower OPCR than the micronised proges...
Source: Cochrane Database of Systematic Reviews - November 30, 2023 Category: General Medicine Authors: Demi án Glujovsky Romina Pesce Mariana Miguens Carlos Sueldo Agust ín Ciapponi Source Type: research
Progestogens for prevention of luteinising hormone (LH) surge in women undergoing controlled ovarian hyperstimulation as part of an assisted reproductive technology (ART) cycle
CONCLUSIONS: Little or no differences in LBR may exist when comparing MPA 4 mg with GnRH agonists in normo-responders. OPCR may be slightly increased in the MPA 4 mg group, but MPA 4 mg reduces the doses of gonadotropins in comparison to GnRH agonists. Little or no differences in OPCR may exist between progestogens and GnRH antagonists in normo-responders and donors. However, micronised progesterone could improve by 2 to 6 MII oocytes. When comparing one progestogen to another, dydrogesterone suggested slightly lower OPCR than MPA and micronised progesterone, and MPA suggested slightly lower OPCR than the micronised proges...
Source: Cochrane Database of Systematic Reviews - November 30, 2023 Category: General Medicine Authors: Demi án Glujovsky Romina Pesce Mariana Miguens Carlos Sueldo Agust ín Ciapponi Source Type: research
Progestogens for prevention of luteinising hormone (LH) surge in women undergoing controlled ovarian hyperstimulation as part of an assisted reproductive technology (ART) cycle
CONCLUSIONS: Little or no differences in LBR may exist when comparing MPA 4 mg with GnRH agonists in normo-responders. OPCR may be slightly increased in the MPA 4 mg group, but MPA 4 mg reduces the doses of gonadotropins in comparison to GnRH agonists. Little or no differences in OPCR may exist between progestogens and GnRH antagonists in normo-responders and donors. However, micronised progesterone could improve by 2 to 6 MII oocytes. When comparing one progestogen to another, dydrogesterone suggested slightly lower OPCR than MPA and micronised progesterone, and MPA suggested slightly lower OPCR than the micronised proges...
Source: Cochrane Database of Systematic Reviews - November 30, 2023 Category: General Medicine Authors: Demi án Glujovsky Romina Pesce Mariana Miguens Carlos Sueldo Agust ín Ciapponi Source Type: research
Progestogens for prevention of luteinising hormone (LH) surge in women undergoing controlled ovarian hyperstimulation as part of an assisted reproductive technology (ART) cycle
CONCLUSIONS: Little or no differences in LBR may exist when comparing MPA 4 mg with GnRH agonists in normo-responders. OPCR may be slightly increased in the MPA 4 mg group, but MPA 4 mg reduces the doses of gonadotropins in comparison to GnRH agonists. Little or no differences in OPCR may exist between progestogens and GnRH antagonists in normo-responders and donors. However, micronised progesterone could improve by 2 to 6 MII oocytes. When comparing one progestogen to another, dydrogesterone suggested slightly lower OPCR than MPA and micronised progesterone, and MPA suggested slightly lower OPCR than the micronised proges...
Source: Cochrane Database of Systematic Reviews - November 30, 2023 Category: General Medicine Authors: Demi án Glujovsky Romina Pesce Mariana Miguens Carlos Sueldo Agust ín Ciapponi Source Type: research
Progestogens for prevention of luteinising hormone (LH) surge in women undergoing controlled ovarian hyperstimulation as part of an assisted reproductive technology (ART) cycle
CONCLUSIONS: Little or no differences in LBR may exist when comparing MPA 4 mg with GnRH agonists in normo-responders. OPCR may be slightly increased in the MPA 4 mg group, but MPA 4 mg reduces the doses of gonadotropins in comparison to GnRH agonists. Little or no differences in OPCR may exist between progestogens and GnRH antagonists in normo-responders and donors. However, micronised progesterone could improve by 2 to 6 MII oocytes. When comparing one progestogen to another, dydrogesterone suggested slightly lower OPCR than MPA and micronised progesterone, and MPA suggested slightly lower OPCR than the micronised proges...
Source: Cochrane Database of Systematic Reviews - November 30, 2023 Category: General Medicine Authors: Demi án Glujovsky Romina Pesce Mariana Miguens Carlos Sueldo Agust ín Ciapponi Source Type: research
Treatment of Paraphilic Disorder Using Medroxyprogesterone Acetate
Prim Care Companion CNS Disord. 2023 Nov 14;25(6):23cr03558. doi: 10.4088/PCC.23cr03558.NO ABSTRACTPMID:37976224 | DOI:10.4088/PCC.23cr03558 (Source: The Primary Care Companion for CNS Disorders)
Source: The Primary Care Companion for CNS Disorders - November 17, 2023 Category: Primary Care Authors: Aishwarya Kumar Raja Mogallapu Nycole Kothe Michael Ang-Rabanes Rikinkumar S Patel Source Type: research
Treatment of Paraphilic Disorder Using Medroxyprogesterone Acetate
Prim Care Companion CNS Disord. 2023 Nov 14;25(6):23cr03558. doi: 10.4088/PCC.23cr03558.NO ABSTRACTPMID:37976224 | DOI:10.4088/PCC.23cr03558 (Source: Primary Care)
Source: Primary Care - November 17, 2023 Category: Primary Care Authors: Aishwarya Kumar Raja Mogallapu Nycole Kothe Michael Ang-Rabanes Rikinkumar S Patel Source Type: research
Treatment of Paraphilic Disorder Using Medroxyprogesterone Acetate
Prim Care Companion CNS Disord. 2023 Nov 14;25(6):23cr03558. doi: 10.4088/PCC.23cr03558.NO ABSTRACTPMID:37976224 | DOI:10.4088/PCC.23cr03558 (Source: The Primary Care Companion for CNS Disorders)
Source: The Primary Care Companion for CNS Disorders - November 17, 2023 Category: Primary Care Authors: Aishwarya Kumar Raja Mogallapu Nycole Kothe Michael Ang-Rabanes Rikinkumar S Patel Source Type: research
Treatment of Paraphilic Disorder Using Medroxyprogesterone Acetate
Prim Care Companion CNS Disord. 2023 Nov 14;25(6):23cr03558. doi: 10.4088/PCC.23cr03558.NO ABSTRACTPMID:37976224 | DOI:10.4088/PCC.23cr03558 (Source: Primary Care)
Source: Primary Care - November 17, 2023 Category: Primary Care Authors: Aishwarya Kumar Raja Mogallapu Nycole Kothe Michael Ang-Rabanes Rikinkumar S Patel Source Type: research
Treatment of Paraphilic Disorder Using Medroxyprogesterone Acetate
Prim Care Companion CNS Disord. 2023 Nov 14;25(6):23cr03558. doi: 10.4088/PCC.23cr03558.NO ABSTRACTPMID:37976224 | DOI:10.4088/PCC.23cr03558 (Source: The Primary Care Companion for CNS Disorders)
Source: The Primary Care Companion for CNS Disorders - November 17, 2023 Category: Primary Care Authors: Aishwarya Kumar Raja Mogallapu Nycole Kothe Michael Ang-Rabanes Rikinkumar S Patel Source Type: research
